Sector: Health Care
Director information for VERACYTE INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Brent Shafer | Chair, Baxter International, Inc. and Board of Directors member, Tactile Systems Technology, Inc.; Chairman of the Board | 68 | ["Veteran healthcare industry leader","Over 40 years of experience in health information technology and medical devices","Former Chairman and Chief Executive Officer of Cerner Corporation","Held key roles at Royal Philips","Vice President and General Manager of Hillrom’s Patient Care Environment Division","Experience at GE Medical Systems and Hewlett-Packard’s Medical Products Group","Board member of Tactile Systems Technology, Inc.","Holds a B.S. in Communications from the University of Utah","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing"] | ["Compensation"] | 2026 |
| Eliav Barr | Member | ["Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing"] | ["Regulatory and Compliance Committee"] | 2026 | |
| Eliav Barr, M.D. | Head of Global Clinical Development and Chief Medical Officer, Merck Research Laboratories | 61 | ["Head of Global Clinical Development at Merck Research Laboratories","Chairperson of the Late Development Review Committee","Senior Vice President, Global Medical and Scientific Affairs"] | ["Audit","Regulatory and Compliance"] | 2026 |
| Evan Jones | $Managing member, jVen Capital, LLC; Chair | 69 | ["B.A. in biochemistry from the University of Colorado","M.B.A. from The Wharton School at the University of Pennsylvania","knowledge of the life sciences industry","experience as a chief executive officer","experience as a board member of other publicly traded and privately held life sciences companies","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing","audit committee financial expert"] | ["Audit","Nominating and Corporate Governance","Regulatory and Compliance","Audit Committee","Regulatory and Compliance Committee"] | 2026 |
| Jens Holstein | $Former Chief Financial Officer, BioNTech SE; Director; Chair | 62 | ["Chief Financial Officer of BioNTech SE","Chief Financial Officer of MorphoSys AG","Various positions at Fresenius SE & Co. KGaA","Director of InflaRx N.V.","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing","audit committee financial expert"] | ["Compensation","Audit","Audit (Chair)","Audit Committee"] | 2026 |
| John Leite, Ph.D. | Global Chief Commercial Officer | 54 | ["Global Chief Commercial Officer since November 2024","Senior Vice President, General Manager, Pulmonology & Market Access at Veracyte from September 2022","Chief Business Officer for Venn Biosciences Corporation from 2020 to 2022","Various leadership positions at Illumina, Inc. from 2014 to 2020","Vice President of Commercial Strategy and Market Access at Genoptix Medical Laboratories","B.S. in Biochemistry from Rutgers University","Ph.D. in Biochemistry and Molecular Genetics from the University of Pittsburgh School of Medicine","Post-doctoral work as a National Research Service Award Fellow at the California Institute of Technology"] | [] | 2026 |
| Karin Eastham | $Board of Directors member, Personalis, Inc. | 76 | ["served on the board of directors of Personalis, Inc.","chair of the board of directors of Personalis, Inc.","served on the boards of directors of Nektar Therapeutics","served on the boards of directors of Geron Corporation","Executive Vice President and Chief Operating Officer of the Burnham Institute for Medical Research","Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation","previously served on the board of directors of Illumina, Inc.","extensive senior management experience in the biopharmaceutical industry","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing","audit committee financial expert"] | ["Audit","Compensation","Audit Committee"] | 2026 |
| Kevin Haas, Ph.D. | Chief Development and Technology Officer | 41 | ["More than 15 years of life sciences industry experience","Led teams across technology, research, and development","Expertise in creating automated lab technology and AI systems","Experience in launching scalable molecular assays","Holds a B.S. from University of Wisconsin-Madison","Holds a Ph.D. in Chemical Engineering from University of California-Berkeley"] | [] | 2026 |
| Marc Stapley | Chief Executive Officer, Veracyte; Chief Executive Officer and Director | 56 | ["significant leadership experience in the diagnostics and genetic sequencing fields","experience as Chief Executive Officer","service on the boards of directors of other life sciences and healthcare companies","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing"] | [] | 2026 |
| Muna Bhanji | Founder and President; Member | 63 | ["Founder and President of Tiba Global Access LLC","Over 34-year tenure at Merck in senior leadership roles","Experience in strategic roles in the biopharmaceutical industry","Director on the board of numerous companies","Bachelor of Pharmacy degree from Rutgers School of Pharmacy","M.B.A. from St. Joseph’s University","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing"] | ["Nominating and Corporate Governance","Regulatory and Compliance","Regulatory and Compliance Committee"] | 2026 |
| Muna Bhanji, R.Ph. | Founder and President, Tiba Global Access LLC | 63 | [] | ["Audit","Compensation"] | 2026 |
| Phillip Febbo, M.D. | Chief Scientific Officer, Chief Medical Officer | 59 | ["Chief Medical Officer at Illumina, Inc. (2018-2023)","CMO of Genomic Health, Inc. (2013-2018)","Professor of Medicine and Urology at UCSF","B.A. in Biology from Dartmouth College","M.D. from UCSF","Internal medicine residency at Brigham and Women’s Hospital","Fellowship in oncology at Dana-Farber Cancer Institute","Attending Physician in the Genitourinary Oncology Center at Dana-Farber","Instructor at Harvard Medical School","Post-doctoral fellow in Dr. Todd Golub’s laboratory"] | ["Regan Udall Foundation for the FDA","Conquer Cancer Foundation of ASCO"] | 2026 |
| Robert Epstein | ["Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing"] | [] | 2026 | ||
| Robert S. Epstein, M.D., M.S. | «Board of Directors member, Fate Therapeutics, Inc. and Illumina, Inc.; Chair of the Board of Directors | 70 | ["Strategic consultant to life sciences companies since 2013","Former President of the Medco-UBC Division","Chief Research and Development Officer of Medco Health Solutions, Inc.","Chief Medical Officer of Medco from 1997 to 2010","Board member of Fate Therapeutics, Inc. since March 2014","Board member of Illumina, Inc. since November 2012","Former board member of Aveo Pharmaceuticals, Inc. from 2012 to 2014","Former Chairman of the Board of Decipher Biosciences, Inc. from 2019 to 2021","Former president of the International Society of Pharmacoeconomics and Outcomes Research","Served on the board of directors of the Drug Information Association","Served on the board of the International Society of Quality of Life","Experience with Centers for Disease Control and Prevention Committee","Experience with Agency for Healthcare Research and Quality Committee","Holds a B.S. in Biomedical Science","Holds an M.D. from the University of Michigan","Holds an M.S. in Preventive Medicine from the University of Maryland"] | ["Compensation","Nominating and Corporate Governance"] | 2026 |
| Tom Miller | Member | ["Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing"] | ["Regulatory and Compliance Committee"] | 2026 | |
| Tom Miller, Ph.D. | $Co-founder and Chief Executive Officer, Iambic Therapeutics | 47 | ["Scientist and entrepreneur","Co-founder and Chief Executive Officer of Iambic Therapeutics","Over ten years as a professor at California Institute of Technology","Expertise in AI, emerging technologies and data analytics","B.S. in Chemistry and Mathematics from Texas A&M University","Ph.D. in Theoretical Chemistry from the University of Oxford"] | ["Regulatory and Compliance"] | 2026 |
